Share-based Payment Arrangement, Expense in USD of ReShape Lifesciences Inc. from Q2 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ReShape Lifesciences Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2020 to Q3 2025.
  • ReShape Lifesciences Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $574K, a 1694% increase year-over-year.
  • ReShape Lifesciences Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $616K, a 120% increase year-over-year.
  • ReShape Lifesciences Inc. annual Share-based Payment Arrangement, Expense for 2024 was $184K, a 76% decline from 2023.
  • ReShape Lifesciences Inc. annual Share-based Payment Arrangement, Expense for 2023 was $766K, a 63.3% decline from 2022.
  • ReShape Lifesciences Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.09M, a 82.9% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

ReShape Lifesciences Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $616K $574K +$542K +1694% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-14
Q2 2025 $74K $12K -$53K -81.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 $127K $15K -$57K -79.2% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-20
Q4 2024 $184K $15K -$96K -86.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-04-04
Q3 2024 $280K $32K -$184K -85.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $464K $65K -$152K -70% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 $616K $72K -$150K -67.6% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-20
Q4 2023 $766K $111K -$128K -53.6% Oct 1, 2023 Dec 31, 2023 10-K 2025-04-04
Q3 2023 $894K $216K -$143K -39.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $1.04M $217K -$553K -71.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $1.59M $222K -$497K -69.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $2.09M $239K -$1.53M -86.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 $3.62M $359K -$10.4M -96.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $14M $770K +$1.13M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $12.8M $719K +$618K +612% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $12.2M $1.77M Oct 1, 2021 Dec 31, 2021 10-K 2023-04-17
Q3 2021 $10.7M +$10.5M +4104% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$364K -$711K -205% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-19
Q1 2021 $101K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-23
Q3 2020 $255K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $347K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16

ReShape Lifesciences Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $184K -$582K -76% Jan 1, 2024 Dec 31, 2024 10-K 2025-04-04
2023 $766K -$1.32M -63.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-04-04
2022 $2.09M -$10.1M -82.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-04-01
2021 $12.2M +$10.9M +824% Jan 1, 2021 Dec 31, 2021 10-K 2023-04-17
2020 $1.32M Jan 1, 2020 Dec 31, 2020 10-K 2022-04-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.